MTOR and Merkel cell skin cancer: Mechanistically, results from a series of cellular and biochemical experiments demonstrate that copanlisib inhibits PI3K/AKT/mTOR pathway activities and represses MCC cell proliferation and survival more potently than idelalisib in MCC-3, −9, and −21.